Amyloid Beta and Transition Metals: Structure and Reactivity
Principal Investigator
Veronika Szalai, PhD
University of Maryland Baltimore County
Baltimore, MD, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2003 - March 31, 2006
Grant ID
A2003227
Summary
The diagnosis of Alzheimer’s disease (AD) is determined by the appearance of neuro-fibrillary tangles and amyloid plaques in brain tissue. Amyloid plaques are composed of repeating units of the protein amyloid-beta (Aß). While the global structure of amyloid plaques has to a great extent been revealed, local structural factors are not well understood. Transition metal ions like copper, zinc and iron have been observed to both increase and decrease the rate of Aß aggregation in vitro. The transition metals may not play an exclusively structural role in the biochemistry of Aß. The levels of copper ions are increased in the vicinity of amyloid plaques, yet decreased overall in AD-affected brains, implying that transition metal ion homeostasis is affected during the progression of the disease. The finding that transition metal ion levels in brains from AD patients are different from the levels in control samples has led researchers to investigate metal ion involvement in the neurotoxic events. In the presence of Aß in a test tube, some transition metals trap dioxygen to generate species that could potentially lead to neurodamage. The purpose of this study is to investigate the chemistry of metal ions in amyloid plaque neurotoxicity. Because a drug that binds metal ion has already been shown to dissolve amyloid plaques in vitro, the results could be helpful in designing new therapeutic strategies. If the mechanisms of the role of metal ions with Aß can be understood, Dr. Szalai’s team may be able to provide a promising new direction for drug design.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD